Shanqi Guo

Shanqi Guo

Auto-generated profile, based on publicly available information

Shanqi Guo

Department of Oncology, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
XJXingkang Jiang
Xingkang Jiang
YXYong Xu
Yong Xu
RLRanlu Liu
Ranlu Liu
SGShanqi Guo
Shanqi Guo
Emerging evidence has suggested that patients with metastatic prostate cancer will become resistant after receiving docetaxel (DTX) chemotherapy, but the specific regulatory mechanism is still unclear. lincROR is an important oncogenic long noncoding RNA which plays an important role in regulating tumor carcinogenesis and metastasis; however, the underlying mechanism of lincROR functioning in the DTX resistance process of prostate cancer remains largely unknown. In the current study, we found that lincROR is highly expressed in DTX-resistant prostate cancer cell lines and was associated with poor DTX response in patients with metastatic prostate cancer. By using loss- and gain-of-function experiments revealed that lincROR promotes prostate cancer cells growth and DTX resistance in vitro and in vivo. Mechanistic studies demonstrated that lincROR specifically interacts with and stabilizes MYH9 protein, which enhances β-catenin/hypoxia-inducible factor 1-alpha (HIF1α) pathways. Besides, HIF1α could bind with the promoter region of lincROR to activate its transcription, thus forming the lincROR/MYH9/HIF1α positive feedback loop. Moreover, lincROR could be packaged into exosomes in an heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1)-dependent manner and then disseminated chemoresistance phenotype to receipt cells. Overall, our study provides evidence supporting exosome-mediated lincROR activates the β-catenin/HIF1α positive feedback loop by targeting MYH9 protein, which may be exploited for anticancer therapy. Implications: Our findings suggest that targeting hypoxia stress and chemoresistance for therapeutic purposes and lincROR could promote the improvement of treatment responses in patients with DTX-resistant prostate cancer.

20 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJunxin Wang
Junxin Wang
MCMingzhe Chen
Mingzhe Chen
SGShanqi Guo
Shanqi Guo
YXYong Xu
Yong Xu
LLLiwei Liu
Liwei Liu
XJXingkang Jiang
Xingkang Jiang
To develop and validate biopsy-free nomograms to more accurately predict clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate imaging reporting and data system (PI-RADS) ≥ 4 lesions. A cohort of 931 patients with PI-RADS ≥ 4 lesions, undergoing prostate biopsies or radical prostatectomy from January 2020 to August 2023, was analyzed. Various clinical variables, including age, prostate-specific antigen (PSA) levels, prostate volume (PV), PSA density (PSAD), prostate health index (PHI), and maximum standardized uptake values (SUVmax) from PSMA PET-CT imaging, were assessed for predicting csPCa. Model performance was evaluated using area under the receiver operating characteristic curve (AUC), calibration plots, and decision-curve analyses, with internal validation. The foundational model (nomogram 1) encompassed the entire cohort, accurately predicting csPCa by incorporating variables such as age, PSAD, PV, PSA ratio variations, suspicious lesion location, and history of acute urinary retention (AUR). The AUC for csPCa prediction achieved by the foundational model was 0.918, with internal validation confirming reliability (AUC: 0.908). Advanced models (nomogram 2 and 3), incorporating PHI and PHI + PSMA SUVmax, achieved AUCs of 0.908 and 0.955 in the training set and 0.847 and 0.949 in the validation set, respectively. Decision analysis indicated enhanced biopsy outcome predictions with the advanced models. Nomogram 3 could potentially reduce biopsies by 92.41%, while missing only 1.53% of csPCa cases. In conclusion, the newly biopsy-free approaches for patients with PI-RADS ≥ 4 lesions represent a significant advancement in csPCa diagnosis in this high-risk population.

4 January 2022 in Trials
Verified
Journal Article
Open access
PDF file
YZYao Zhang
Yao Zhang
SGShanqi Guo
Shanqi Guo
CWChaoran Wang
Chaoran Wang
DLDillys Xiaodi Liu
Dillys Xiaodi Liu
YLYan Liu
Yan Liu
YJYingjie Jia
Yingjie Jia
Background: Urinary incontinence is a common complication post radical prostatectomy. Acupuncture is considered an effective treatment for post-prostatectomy incontinence (PPI), but the evidence is still limited. We propose to evaluate the effectiveness of acupuncture in a rigorously conducted trial. Methods: Twenty hospitals will recruit 340 participants with urinary incontinence after radical prostatectomy in China from April 2021 to April 2022. Participants will be randomly allocated to acupuncture or sham acupuncture with a 1:1 ratio using computerized simple random sampling. The study plan consists of 1-week baseline, 6-week treatment, and 18-week follow-up. Eighteen 30-min sessions of acupuncture or sham acupuncture treatment will be provided between weeks 1 and 6. The primary outcome is the change in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI-SF) score at the week 6 from the baseline. Secondary outcomes include the change in volume of urine leakage at weeks 4 and 6 from a baseline measured using the 1-h pad test; 72-h incontinence episode frequency based on a 72-h voiding diary; change in the Expanded prostate cancer Index Composite scale (EPIC-26); change in the Self-Rating Anxiety Scale; weekly consumption of pads; and the severity of urinary incontinence based on a 72-h bladder diary and self-assessment of the therapeutic effect. The safety of acupuncture will also be assessed. Discussion: This trial will help to identify whether acupuncture is effective for PPI, and, if so, whether it exerts a therapeutic rather than a placebo effect. Trial Registration: www.Chictr.org.cnChiCTR2100042500. Retrospectively registered on 22 January 2021.

1 November 2024 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
WLWei Liu
Wei Liu
SGShan-Qi Guo
Shan-Qi Guo
XXXiong Xiao
Xiong Xiao
YWYong Wang
Yong Wang
RLRan-Lu Liu
Ran-Lu Liu
XJXingkang Jiang
Xingkang Jiang
Background: Prostate cancer (PCa) has emerged as one of the most common malignancies among men globally. However, its pathogenesis, clinical features, and treatment responses in younger patients (aged 60 years or below) remain underexplored. This study aims to evaluate the distinctive clinical features, treatment strategies, and oncological outcomes of PCa in men aged 60 years or younger over a 10-year period at a single urological center. Methods: We retrospectively analyzed data from The Second Hospital of Tianjin Medical University, spanning January 2010 to June 2020. The study included patients aged ≤60 years who underwent prostate biopsies. We examined clinical characteristics, pathological findings, treatment approaches, and survival outcomes using t-tests and chi-square tests. Adjusted linear regression models evaluated the relationships between treatment modalities and outcomes, while Kaplan-Meier survival analysis and Cox regression assessed progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). Results: Of the 5,686 patients who underwent prostate biopsy, 643 (11.3%) were ≤60 years old. Among these, 42.8% (275/643) were diagnosed with PCa, with 59.6% presenting at advanced stages. Compared to those with negative pathology, patients with PCa were older and more likely to have hypertension, alcohol consumption, and metabolic syndrome. Most patients (69.8%) received definitive local therapy, while 22.2% opted for palliative care and 8.0% were loss to follow-up. The median follow-up period for the entire cohort was 28.0 months and the median PFS was 77.0 months. For patients receiving definitive local therapy, the median CSS and OS were not reached, while those undergoing palliative therapy had median CSS and OS of 52.0 and 59.0 months, respectively. Multivariable analysis identified prostate-specific antigen >20 ng/mL, International Society of Urological Pathology >3, bone metastasis, and localized treatment as independent factors affecting PFS. Propensity score matching showed that definitive therapy led to superior PFS compared to palliative therapy for patients with localized PCa and a life expectancy of over 5 years. Conclusions: Our findings highlight the influence of incidence, diagnostic characteristics, and treatment methods in younger men with PCa, emphasizing the need to identify specific risk factors and treatment response patterns. Further large-scale, multi-center research is necessary to improve diagnosis and outcomes for PCa patients in this age group.

1 March 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
SGShanqi Guo
Shanqi Guo
XJXingkang Jiang
Xingkang Jiang
Background and Objective: Traditionally, patients with positive magnetic resonance imaging (MRI) results [i.e., Prostate Imaging-Reporting and Data System (PI-RADS) ≥3] would have to undergo both targeted and systematic biopsies. The 2024 European Urology Association guidelines now recommend incorporating perilesional sampling with targeted biopsy; however, these recommendations have not yet been widely adopted. This review aims to examine recent advancements in personalized prostate biopsy techniques to enhance cancer detection through tailored approaches. Methods: We conducted a narrative review to highlight recent advancements in personalized prostate biopsy techniques, emphasizing the roles of serum prostate-specific antigen (PSA) levels, prostate volume (PV), PSA density (PSAD), region of interest (ROI), and PI-RADS scores. Key Content and Findings: This review discusses personalized prostate biopsy protocols, integrating PSA levels, PV, PSAD, and PI-RADS scores. Tumor localization can be refined using transrectal or transperineal approaches. For patients with lower PSA levels (4–19.99 ng/mL), smaller PSAD (50 ng/mL), PSAD (>0.2 ng/mL/cc), or PI-RADS 5 lesions. Variability in cut-off values across studies precludes meta-analysis, limiting our work to a systematic review. Conclusions: Personalized prostate biopsy protocols considering PSA levels, PV, PSAD, ROI, and PI-RADS scores can improve prostate cancer detection accuracy. Further research and clinical validation are needed to optimize these personalized methods.

4 August 2025 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
MCMingzhe Chen
Mingzhe Chen
SGShanqi Guo
Shanqi Guo
BMBaojie Ma
Baojie Ma
NWNan Wang
Nan Wang
JTJing Tian
Jing Tian
XJXingkang Jiang
Xingkang Jiang